Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
49.00
-0.13 (-0.26%)
Feb 18, 2026, 10:01 AM EST

Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of 218.82 billion. The enterprise value is 235.26 billion.

Market Cap218.82B
Enterprise Value 235.26B

Important Dates

The last earnings date was Wednesday, February 4, 2026.

Earnings Date Feb 4, 2026
Ex-Dividend Date Mar 28, 2025

Share Statistics

Current Share Class 3.37B
Shares Outstanding n/a
Shares Change (YoY) -0.34%
Shares Change (QoQ) +0.06%
Owned by Insiders (%) 0.02%
Owned by Institutions (%) 28.53%
Float 3.19B

Valuation Ratios

The trailing PE ratio is 13.59 and the forward PE ratio is 14.88.

PE Ratio 13.59
Forward PE 14.88
PS Ratio 4.50
PB Ratio 7.17
P/TBV Ratio 21.75
P/FCF Ratio 23.61
P/OCF Ratio 11.69
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.60, with an EV/FCF ratio of 25.38.

EV / Earnings 14.61
EV / Sales 4.81
EV / EBITDA 9.60
EV / EBIT 10.58
EV / FCF 25.38

Financial Position

The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.67.

Current Ratio 0.80
Quick Ratio 0.54
Debt / Equity 0.67
Debt / EBITDA 0.85
Debt / FCF 2.22
Interest Coverage 33.42

Financial Efficiency

Return on equity (ROE) is 60.70% and return on invested capital (ROIC) is 41.13%.

Return on Equity (ROE) 60.70%
Return on Assets (ROA) 17.43%
Return on Invested Capital (ROIC) 41.13%
Return on Capital Employed (ROCE) 42.97%
Weighted Average Cost of Capital (WACC) 6.13%
Revenue Per Employee 702,650
Profits Per Employee 232,881
Employee Count69,505
Asset Turnover 0.61
Inventory Turnover 1.20

Taxes

In the past 12 months, Novo Nordisk has paid 4.42 billion in taxes.

Income Tax 4.42B
Effective Tax Rate 21.53%

Stock Price Statistics

The stock price has decreased by -37.16% in the last 52 weeks. The beta is 0.40, so Novo Nordisk's price volatility has been lower than the market average.

Beta (5Y) 0.40
52-Week Price Change -37.16%
50-Day Moving Average 53.31
200-Day Moving Average 58.02
Relative Strength Index (RSI) 41.68
Average Volume (20 Days) 294,660

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of 48.59 billion and earned 16.10 billion in profits. Earnings per share was 3.62.

Revenue48.59B
Gross Profit 40.04B
Operating Income 22.11B
Pretax Income 20.52B
Net Income 16.10B
EBITDA 24.10B
EBIT 22.11B
Earnings Per Share (EPS) 3.62
Full Income Statement

Balance Sheet

The company has 4.24 billion in cash and 20.59 billion in debt, with a net cash position of -16.35 billion.

Cash & Cash Equivalents 4.24B
Total Debt 20.59B
Net Cash -16.35B
Net Cash Per Share n/a
Equity (Book Value) 30.51B
Book Value Per Share 6.86
Working Capital -6.79B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 18.72 billion and capital expenditures -9.45 billion, giving a free cash flow of 9.27 billion.

Operating Cash Flow 18.72B
Capital Expenditures -9.45B
Free Cash Flow 9.27B
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 82.41%, with operating and profit margins of 45.50% and 33.14%.

Gross Margin 82.41%
Operating Margin 45.50%
Pretax Margin 42.24%
Profit Margin 33.14%
EBITDA Margin 49.60%
EBIT Margin 45.50%
FCF Margin 19.08%

Dividends & Yields

This stock pays an annual dividend of 1.66, which amounts to a dividend yield of 3.34%.

Dividend Per Share 1.66
Dividend Yield 3.34%
Dividend Growth (YoY) n/a
Years of Dividend Growth 2
Payout Ratio 50.53%
Buyback Yield 0.34%
Shareholder Yield 3.68%
Earnings Yield 7.36%
FCF Yield 4.24%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.

Last Split Date Sep 13, 2023
Split Type Forward
Split Ratio 2

Scores

Novo Nordisk has an Altman Z-Score of 5.15 and a Piotroski F-Score of 5.

Altman Z-Score 5.15
Piotroski F-Score 5